这例EGFR阳性NSCLC患者的治疗,你怎么看?

2019-01-09 刘雨桃 中国医学论坛报今日肿瘤

女性患者,63岁,无吸烟史,无既往病史。

病例简介

女性患者,63岁,无吸烟史,无既往病史。

2013年10月,因“刺激性干咳1个月”就诊。外院CT发现左肺占位2 cm×3 cm,纵隔、肺门、左侧锁骨上多发淋巴结肿大,多发肝转移。外院ECT示左肱骨、胸腰椎、骶骨骨转移。锁骨上淋巴结穿刺病理示转移性腺癌。锁骨上淋巴结活检示EGFR基因19外显子突变。


右肺腺癌(IV期);纵隔、肺门、右侧锁骨上多发淋巴结转移;多发肝转移;多发骨转移

诊治经过

2013年11月,接受吉非替尼、双膦酸盐治疗。



2015年6月,CT示左肺结节增大,继续单药维持治疗。2015年10月,CT示左肺结节明显增大,附件区及肾上腺发现转移病灶,病情评价为疾病进展(PD)。



脑磁共振成像(MRI):双侧大脑半球、小脑半球转移。



左肺肿物穿刺:腺癌。EGFR基因:19外显子突变,20外显子T790M突变。入组AURA3临床研究,随机分组至培美曲塞+顺铂治疗组,治疗后可见一定程度的肿瘤缩小;脑部未做额外干预,但脑部结节也可见缩小。



2015年10月~2015年12月,接受培美曲塞+顺铂化疗4周期。2016年1月~2016年2月,培美曲塞单药维持治疗2周期。CT示左肺上叶结节较前增大,新出现左侧锁骨上、肺门淋巴结转移,肾上腺转移较前增大;肝转移同前相仿。脑MRI示脑转移同前相仿。



对锁骨上淋巴结新出现的转移病灶进行活检,T790M突变为阴性。2016年3月~2016年5月,接受奥希替尼(AZD9291)治疗。CT示左肺上叶结节、锁骨上淋巴结、右侧肾上腺较前增大;双侧大脑、小脑转移结节较前缩小。血液检测示EGFR19外显子突变。



2016年6月,第三次左侧锁骨上淋巴结活检示c-Met FISH阳性。入组BPI-9016临床试验,疗效评价由疾病稳定(SD)转为PD。



2016年8月30日~9月11日接受脑放疗。2016年9月29日~2016年10月20日接受克唑替尼治疗,左肺不张改善,但肝转移病灶增加,因患者一般情况较差,未能进行肝穿刺。



2016年10月~2016年11月,接受INC280+吉非替尼治疗,左肺病灶明显缩小,但肝转移病灶持续增加。



2016年12月,患者去世,总生存(OS)期为38个月。 

附:讲者简介

刘雨桃,中国医学科学院肿瘤医院内科副主任医师,肿瘤学博士,硕士生导师。
国家卫计委《原发性肺癌诊疗规范(2015年版)》学术委员会学术秘书,中华慈善总会易瑞沙慈善援助项目专家委员会委员,北京医学奖励基金肺癌医学青年专家委员会 副主任委员,全国中西医肿瘤防治专家委员会常务委员兼青委会副主任委员,中国医疗保健国际交流促进会健康科普分会委员,中国医促会神经内分泌肿瘤分会青年委员。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1816342, encodeId=84e4181634215, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97502, encryptionId=28dd9e5029b, topicName=阳性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XhttJCp4Aq9gKA5n4v9elclQlVQTDenMiaEiadlI5D3gtmfSiaicoIY4ZsuibrQKLibDdxBKVY8oS6B2FicqJlT93clow/132, createdBy=03202500144, createdName=ms7258648636991762, createdTime=Sun Jun 02 04:30:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068972, encodeId=62ce20689e21f, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Aug 03 05:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082085, encodeId=9c9020820852d, content=<a href='/topic/show?id=27b2660581' target=_blank style='color:#2F92EE;'>#EGFR阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6605, encryptionId=27b2660581, topicName=EGFR阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Fri Aug 16 15:30:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410829, encodeId=a33414108294e, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Jan 10 23:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534407, encodeId=7a97153440ede, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Jan 10 23:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1816342, encodeId=84e4181634215, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97502, encryptionId=28dd9e5029b, topicName=阳性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XhttJCp4Aq9gKA5n4v9elclQlVQTDenMiaEiadlI5D3gtmfSiaicoIY4ZsuibrQKLibDdxBKVY8oS6B2FicqJlT93clow/132, createdBy=03202500144, createdName=ms7258648636991762, createdTime=Sun Jun 02 04:30:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068972, encodeId=62ce20689e21f, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Aug 03 05:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082085, encodeId=9c9020820852d, content=<a href='/topic/show?id=27b2660581' target=_blank style='color:#2F92EE;'>#EGFR阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6605, encryptionId=27b2660581, topicName=EGFR阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Fri Aug 16 15:30:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410829, encodeId=a33414108294e, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Jan 10 23:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534407, encodeId=7a97153440ede, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Jan 10 23:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=)]
    2019-08-03 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1816342, encodeId=84e4181634215, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97502, encryptionId=28dd9e5029b, topicName=阳性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XhttJCp4Aq9gKA5n4v9elclQlVQTDenMiaEiadlI5D3gtmfSiaicoIY4ZsuibrQKLibDdxBKVY8oS6B2FicqJlT93clow/132, createdBy=03202500144, createdName=ms7258648636991762, createdTime=Sun Jun 02 04:30:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068972, encodeId=62ce20689e21f, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Aug 03 05:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082085, encodeId=9c9020820852d, content=<a href='/topic/show?id=27b2660581' target=_blank style='color:#2F92EE;'>#EGFR阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6605, encryptionId=27b2660581, topicName=EGFR阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Fri Aug 16 15:30:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410829, encodeId=a33414108294e, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Jan 10 23:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534407, encodeId=7a97153440ede, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Jan 10 23:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1816342, encodeId=84e4181634215, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97502, encryptionId=28dd9e5029b, topicName=阳性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XhttJCp4Aq9gKA5n4v9elclQlVQTDenMiaEiadlI5D3gtmfSiaicoIY4ZsuibrQKLibDdxBKVY8oS6B2FicqJlT93clow/132, createdBy=03202500144, createdName=ms7258648636991762, createdTime=Sun Jun 02 04:30:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068972, encodeId=62ce20689e21f, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Aug 03 05:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082085, encodeId=9c9020820852d, content=<a href='/topic/show?id=27b2660581' target=_blank style='color:#2F92EE;'>#EGFR阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6605, encryptionId=27b2660581, topicName=EGFR阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Fri Aug 16 15:30:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410829, encodeId=a33414108294e, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Jan 10 23:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534407, encodeId=7a97153440ede, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Jan 10 23:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1816342, encodeId=84e4181634215, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97502, encryptionId=28dd9e5029b, topicName=阳性NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XhttJCp4Aq9gKA5n4v9elclQlVQTDenMiaEiadlI5D3gtmfSiaicoIY4ZsuibrQKLibDdxBKVY8oS6B2FicqJlT93clow/132, createdBy=03202500144, createdName=ms7258648636991762, createdTime=Sun Jun 02 04:30:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068972, encodeId=62ce20689e21f, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Aug 03 05:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082085, encodeId=9c9020820852d, content=<a href='/topic/show?id=27b2660581' target=_blank style='color:#2F92EE;'>#EGFR阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6605, encryptionId=27b2660581, topicName=EGFR阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Fri Aug 16 15:30:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410829, encodeId=a33414108294e, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Thu Jan 10 23:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534407, encodeId=7a97153440ede, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Jan 10 23:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=)]
    2019-01-10 liuyiping

相关资讯

JCO:阿法替尼可显著改善EGFR阳性晚期肺腺癌患者症状及生活质量

在2013年7月1日在线出版的《临床肿瘤学杂志》(Journal of Clinical Oncology)上,我国台湾地区台湾大学肿瘤医学研究所的杨志新教授等人公布了LUX-Lung 3临床试验的最新研究成果,该研究通过一项针对阿法替尼或顺铂/培美曲塞的随机临床III期试验,对患者报告的症状及与健康相关的生活质量(QoL)获益情况进行了考察。 研究人员按2:1的比例,对345例表皮生长